WHITEHAWK THERAPEUTICS, INC. Impairment of Intangible Assets, Finite-lived
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2024-03-13
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-06-30 was $3.72M.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-03-31 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $3.72M, a 94.98% decline from fiscal 2021.
- WHITEHAWK THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $74.16M.
| Period end | Impairment of Intangible Assets, Finite-lived | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month | Impairment of Intangible Assets, Finite-lived 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-13 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $3.72M derived: sum of 3 quarters · filed 2024-03-13 | $3.72M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.72M derived: sum of 2 quarters · filed 2023-11-08 | $3.72M 10-Q · filed 2023-11-08 | $73.98M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.72M 10-Q · filed 2023-08-09 | $73.98M derived: sum of 3 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $70.26M derived: sum of 2 quarters · filed 2023-03-29 | ||||
| 2021-12-31 | $70.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $74.16M 10-K · filed 2023-03-29 | $3.90M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $3.90M 10-Q · filed 2021-11-10 | |||||
| 2021-08-26 | $74.20M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |